{
    "name": "methimazole",
    "comment": "Rx",
    "other_names": [
        "Northyx",
        "Tapazole"
    ],
    "classes": [
        "Antithyroid Agents"
    ],
    "source": "https://reference.medscape.com/drug/tapazole-methimazole-342734",
    "pregnancy": {
        "common": [
            "Pregnancy category: D (drug crosses placenta)",
            "Lactation: Drug distributed in breast milk; use contraindicated by manufacturer (American Academy of Pediatrics [AAP] Committee states that drug is compatible with nursing; American Academy of Family Physicians [AAFP] states that it is safe for nursing)"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: Drug distributed in breast milk; use contraindicated by manufacturer (American Academy of Pediatrics [AAP] Committee states that drug is compatible with nursing; American Academy of Family Physicians [AAFP] states that it is safe for nursing)"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity",
                "Breastfeeding"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Lupus-like syndrome reported",
                "Hypoprothrombinemia and bleeding may occur; monitor, especially before surgical procedure performed",
                "Antineutrophil cytoplasmic autoantibody (ANCA)-positive vasculitis reported; discontinue use in presence of vasculitis",
                "Concurrent administration of other agranulocytosis-causing drugs",
                "Prolonged treatment may cause hypothyroidism; routinely monitor free T4 levels and TSH; adjust dose as necessary to maintain euthyroid state",
                "Significant bone marrow suppression may occur; use caution if administered with other agents known to cause myelosupression; discontinue if significan agranulocytosis, leukopenia, or aplastic anemia occurs",
                "Hepatitis reported; discontinue if it occurs or if clinically significant hepatic enzyme levels, including transaminases >3 times upper limit of normal observed",
                "Discontinue if unexplained fever occurs",
                "Antithyroid agents associated with rare but severe dermatologic reactions; discontinue if exfoliative dermatitis occurs"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "eliglustat",
            "description": {
                "common": "methimazole increases levels of eliglustat by affecting hepatic enzyme CYP2D6 metabolism. Contraindicated. If coadministered with strong or moderate CYP2D6 inhibitors, reduce eliglustat dose from 84 mg BID to 84 mg once daily in extensive  and intermediate metabolizers;  eliglustat is contraindiated if strong or moderate CYP2D6 inhibitors are given concomitantly with strong or moderate CYP3A inhibitors."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "sodium iodide I-131",
            "description": {
                "common": "methimazole will decrease the level or effect of sodium iodide I-131 by  Other (see comment). Contraindicated. Discontinue antithyroid medications at least 3-4 days before administering sodium iodide I-131 and do not coadminister; thyroid agents decrease update of sodium iodide I-131 by the thyroid gland"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "carbamazepine",
            "description": {
                "common": "methimazole, carbamazepine.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Increased risk of agranulocytosis."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "clozapine",
            "description": {
                "common": "methimazole, clozapine.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Increased risk of agranulocytosis."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fedratinib",
            "description": {
                "common": "methimazole will increase the level or effect of fedratinib by  Other (see comment). Avoid or Use Alternate Drug. Avoid coadministration of fedratinib (a CYP3A4 and CYP2C19 substrate) with dual CYP3A4 and CYP2C19 inhibitor. Effect of coadministration of a dual CYP3A4 and CYP2C19 inhibitor with fedratinib has not been studied."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lonafarnib",
            "description": {
                "common": "methimazole will increase the level or effect of lonafarnib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration of lonafarnib (a sensitive CYP3A substrate) with weak CYP3A inhibitors is unavoidable, reduce to, or continue lonafarnib at starting dose. Closely monitor for arrhythmias and events (eg, syncope, heart palpitations) since lonafarnib effect on QT interval is unknown."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "propylthiouracil",
            "description": {
                "common": "propylthiouracil, methimazole.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Increased risk of agranulocytosis."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ropeginterferon alfa 2b",
            "description": {
                "common": "ropeginterferon alfa 2b, methimazole.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "antithrombin alfa",
            "description": {
                "common": "methimazole decreases effects of antithrombin alfa by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "antithrombin III",
            "description": {
                "common": "methimazole decreases effects of antithrombin III by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "argatroban",
            "description": {
                "common": "methimazole decreases effects of argatroban by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atogepant",
            "description": {
                "common": "methimazole will increase the level or effect of atogepant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "avapritinib",
            "description": {
                "common": "methimazole will increase the level or effect of avapritinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "axitinib",
            "description": {
                "common": "methimazole increases levels of axitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bemiparin",
            "description": {
                "common": "methimazole decreases effects of bemiparin by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bivalirudin",
            "description": {
                "common": "methimazole decreases effects of bivalirudin by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "brexpiprazole",
            "description": {
                "common": "methimazole will increase the level or effect of brexpiprazole by  affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Administer a quarter of brexpiprazole dose if coadministered with a moderate CYP2D6 inhibitor PLUS a strong/moderate CYP3A4 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dalteparin",
            "description": {
                "common": "methimazole decreases effects of dalteparin by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "enoxaparin",
            "description": {
                "common": "methimazole decreases effects of enoxaparin by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "finerenone",
            "description": {
                "common": "methimazole will increase the level or effect of finerenone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Monitor serum potassium during initiation and dosage adjustment of either finererone or weak CYP3A4 inhibitors. Adjust finererone dosage as needed."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "flibanserin",
            "description": {
                "common": "methimazole will increase the level or effect of flibanserin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Increased flibanserin adverse effects may occur if coadministered with multiple weak CYP3A4 inhibitors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fondaparinux",
            "description": {
                "common": "methimazole decreases effects of fondaparinux by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "heparin",
            "description": {
                "common": "methimazole decreases effects of heparin by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "isavuconazonium sulfate",
            "description": {
                "common": "methimazole will increase the level or effect of isavuconazonium sulfate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ivacaftor",
            "description": {
                "common": "methimazole increases levels of ivacaftor by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor when coadministered with weak CYP3A4 inhibitors ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lemborexant",
            "description": {
                "common": "methimazole will increase the level or effect of lemborexant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Lower nightly dose of lemborexant recommended if coadministered with weak CYP3A4 inhibitors. See drug monograph for specific dosage modification."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lomitapide",
            "description": {
                "common": "methimazole increases levels of lomitapide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Lomitapide dose should not exceed 30 mg/day."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lycopus",
            "description": {
                "common": "lycopus increases effects of methimazole by pharmacodynamic synergism. Use Caution/Monitor. Lycopus blocks peripheral conversion of T4 to T3."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mavacamten",
            "description": {
                "common": "methimazole will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Inititiation of weak CYP2C19 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "midazolam intranasal",
            "description": {
                "common": "methimazole will increase the level or effect of midazolam intranasal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration of mild CYP3A4 inhibitors with midazolam intranasal may cause higher midazolam systemic exposure, which may prolong sedation."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oliceridine",
            "description": {
                "common": "methimazole will increase the level or effect of oliceridine by  affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. If concomitant use is necessary, may require less frequent oliceridine dosing. Closely monitor for respiratory depression and sedation and titrate subsequent doses accordingly. If inhibitor is discontinued, consider increase oliceridine dosage until stable drug effects are achieved. Monitor for signs of opioid withdrawal. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenindione",
            "description": {
                "common": "methimazole decreases effects of phenindione by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "potassium iodide",
            "description": {
                "common": "potassium iodide, methimazole. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Concomitant use with antithyroid drugs may potentiate the hypothyroid and goitrogenic effects of potassium iodide."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "protamine",
            "description": {
                "common": "methimazole decreases effects of protamine by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tamsulosin",
            "description": {
                "common": "methimazole increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tazemetostat",
            "description": {
                "common": "methimazole will increase the level or effect of tazemetostat by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "theophylline",
            "description": {
                "common": "methimazole increases levels of theophylline by decreasing elimination. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tinidazole",
            "description": {
                "common": "methimazole will increase the level or effect of tinidazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "warfarin",
            "description": {
                "common": "methimazole decreases effects of warfarin by unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cadexomer iodine",
            "description": {
                "common": "cadexomer iodine, methimazole. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Additive hypothyroid effects."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "iodinated glycerol",
            "description": {
                "common": "iodinated glycerol, methimazole. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Additive hypothyroid effects."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "iodine",
            "description": {
                "common": "iodine, methimazole. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Additive hypothyroid effects."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ruxolitinib",
            "description": {
                "common": "methimazole will increase the level or effect of ruxolitinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ruxolitinib topical",
            "description": {
                "common": "methimazole will increase the level or effect of ruxolitinib topical by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Agranulocytosis",
            "percent": null
        },
        {
            "name": "Alopecia",
            "percent": null
        },
        {
            "name": "Aplastic anemia",
            "percent": null
        },
        {
            "name": "Dermatologic reactions",
            "percent": null
        },
        {
            "name": "eg",
            "percent": null
        },
        {
            "name": "rash",
            "percent": null
        },
        {
            "name": "pruritus",
            "percent": null
        },
        {
            "name": "skin pigmentation",
            "percent": null
        },
        {
            "name": "Hepatotoxicity",
            "percent": null
        },
        {
            "name": "Leukocytoclastic vasculitis",
            "percent": null
        },
        {
            "name": "Neuritis",
            "percent": null
        },
        {
            "name": "Polyarthritis",
            "percent": null
        },
        {
            "name": "Pruritus",
            "percent": null
        },
        {
            "name": "Salivary gland swelling",
            "percent": null
        },
        {
            "name": "Skin pigmentation",
            "percent": null
        },
        {
            "name": "Thrombocytopenia",
            "percent": null
        },
        {
            "name": "Urticaria",
            "percent": null
        },
        {
            "name": "Vertigo",
            "percent": null
        }
    ]
}